A Roadmap for Integrating Neuroscience into Addiction Treatment: A Consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine

Antonio Verdejo-Garcia (Lead / Corresponding author), Valentina Lorenzetti, Victoria Manning, Hugh Piercy, Raimondo Bruno, Rob Hester, David Pennington, Serenella Tolomeo, Shalini Arunogiri, Marsha E. Bates, Henrietta Bowden-Jones, Salvatore Campanella, Stacey Daughters, Christos Kouimtsidis, Dan I. Lubman, Dieter J. Meyerhoff, Annaketurah Ralph, Tara Rezapour, Hosna Tavakoli, Mehran Zare-BidokyAnna Zilverstand, Douglas Steele, Scott J. Moeller, Martin P. Paulus, Alex Baldacchino, Hamed Ekhtiari

Research output: Contribution to journalArticle

17 Downloads (Pure)

Abstract

Although there is general consensus that altered brain structure and function underpins addictive disorders, clinicians working in addiction treatment rarely incorporate neuroscience-informed approaches into their practice. We recently launched the Neuroscience Interest Group within the International Society of Addiction Medicine (ISAMNIG) to promote initiatives to bridge this gap. This article summarises the ISAM-NIG key priorities and strategies to achieve implementation of addiction neuroscience knowledge and tools forthe assessment and treatment of substance use disorders. We cover two assessment areas: cognitive assessment and neuroimaging, and two interventional areas: cognitive training/remediation and neuromodulation, where we identify key challenges and proposed solutions. We reason that incorporating cognitive assessment into clinical settings requires the identification of constructs that predict meaningful clinical outcomes. Other requirements are the development of measures that are easily-administered, reliable and ecologically-valid. Translation of neuroimaging techniques requires the development of diagnostic and prognostic biomarkers and testing the cost-effectiveness of these biomarkers in individualised prediction algorithms for relapse prevention and treatment selection. Integration of cognitive assessments with neuroimaging can provide multilevel targets including neural, cognitive, and behavioural outcomes for neuroscience-informed interventions. Application of neuroscience-informed interventions including cognitive training/remediation and neuromodulation requires clear pathways to design interventions based on multilevel targets, additional evidence from randomised trials and subsequent clinical implementation, including evaluation of cost-effectiveness. We propose to address these challenges by promoting international collaboration between researchers and clinicians, developing harmonised protocols and data management systems, and prioritising multi-site research that focuses on improving clinical outcomes.
Original languageEnglish
Article number877
Pages (from-to)1-23
Number of pages23
JournalFrontiers in Psychiatry
Volume10
DOIs
Publication statusPublished - 23 Dec 2019

Fingerprint

Public Opinion
Neurosciences
Consensus
Medicine
Neuroimaging
Cost-Benefit Analysis
Biomarkers
Therapeutics
Secondary Prevention
Information Systems
Substance-Related Disorders
Randomized Controlled Trials
Research Personnel
Brain
Research

Keywords

  • Neuroscience
  • Addiction Medicine
  • Treatment
  • Substance Use Disorder
  • fMRI
  • Neuromodulation
  • Cognition
  • Neuropsychological Assessment
  • Cognitive Remediation
  • Cognitive Training

Cite this

Verdejo-Garcia, Antonio ; Lorenzetti, Valentina ; Manning, Victoria ; Piercy, Hugh ; Bruno, Raimondo ; Hester, Rob ; Pennington, David ; Tolomeo, Serenella ; Arunogiri, Shalini ; Bates, Marsha E. ; Bowden-Jones, Henrietta ; Campanella, Salvatore ; Daughters, Stacey ; Kouimtsidis, Christos ; Lubman, Dan I. ; Meyerhoff, Dieter J. ; Ralph, Annaketurah ; Rezapour, Tara ; Tavakoli, Hosna ; Zare-Bidoky, Mehran ; Zilverstand, Anna ; Steele, Douglas ; Moeller, Scott J. ; Paulus, Martin P. ; Baldacchino, Alex ; Ekhtiari, Hamed. / A Roadmap for Integrating Neuroscience into Addiction Treatment : A Consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine. In: Frontiers in Psychiatry. 2019 ; Vol. 10. pp. 1-23.
@article{7ece2bc7ef8948c0b154956e9fadca6e,
title = "A Roadmap for Integrating Neuroscience into Addiction Treatment: A Consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine",
abstract = "Although there is general consensus that altered brain structure and function underpins addictive disorders, clinicians working in addiction treatment rarely incorporate neuroscience-informed approaches into their practice. We recently launched the Neuroscience Interest Group within the International Society of Addiction Medicine (ISAMNIG) to promote initiatives to bridge this gap. This article summarises the ISAM-NIG key priorities and strategies to achieve implementation of addiction neuroscience knowledge and tools forthe assessment and treatment of substance use disorders. We cover two assessment areas: cognitive assessment and neuroimaging, and two interventional areas: cognitive training/remediation and neuromodulation, where we identify key challenges and proposed solutions. We reason that incorporating cognitive assessment into clinical settings requires the identification of constructs that predict meaningful clinical outcomes. Other requirements are the development of measures that are easily-administered, reliable and ecologically-valid. Translation of neuroimaging techniques requires the development of diagnostic and prognostic biomarkers and testing the cost-effectiveness of these biomarkers in individualised prediction algorithms for relapse prevention and treatment selection. Integration of cognitive assessments with neuroimaging can provide multilevel targets including neural, cognitive, and behavioural outcomes for neuroscience-informed interventions. Application of neuroscience-informed interventions including cognitive training/remediation and neuromodulation requires clear pathways to design interventions based on multilevel targets, additional evidence from randomised trials and subsequent clinical implementation, including evaluation of cost-effectiveness. We propose to address these challenges by promoting international collaboration between researchers and clinicians, developing harmonised protocols and data management systems, and prioritising multi-site research that focuses on improving clinical outcomes.",
keywords = "Neuroscience, Addiction Medicine, Treatment, Substance Use Disorder, fMRI, Neuromodulation, Cognition, Neuropsychological Assessment, Cognitive Remediation, Cognitive Training",
author = "Antonio Verdejo-Garcia and Valentina Lorenzetti and Victoria Manning and Hugh Piercy and Raimondo Bruno and Rob Hester and David Pennington and Serenella Tolomeo and Shalini Arunogiri and Bates, {Marsha E.} and Henrietta Bowden-Jones and Salvatore Campanella and Stacey Daughters and Christos Kouimtsidis and Lubman, {Dan I.} and Meyerhoff, {Dieter J.} and Annaketurah Ralph and Tara Rezapour and Hosna Tavakoli and Mehran Zare-Bidoky and Anna Zilverstand and Douglas Steele and Moeller, {Scott J.} and Paulus, {Martin P.} and Alex Baldacchino and Hamed Ekhtiari",
note = "AV-G is supported by Australian Medical Research Future Fund Fellowship (MRF1141214). DM is supported by NIH R01DA039903. MB receives support from NIH R01AA023667. DLP is supported by the Office of Research and Development, Clinical Science Research and Development (CSR&D), Department of Veterans Affairs, Career Development Award—2 (1IK2CX001510-01). SJM was supported by NIH K01DA037452.",
year = "2019",
month = "12",
day = "23",
doi = "10.3389/fpsyt.2019.00877",
language = "English",
volume = "10",
pages = "1--23",
journal = "Frontiers in Psychiatry",
issn = "1664-0640",
publisher = "Frontiers Media",

}

Verdejo-Garcia, A, Lorenzetti, V, Manning, V, Piercy, H, Bruno, R, Hester, R, Pennington, D, Tolomeo, S, Arunogiri, S, Bates, ME, Bowden-Jones, H, Campanella, S, Daughters, S, Kouimtsidis, C, Lubman, DI, Meyerhoff, DJ, Ralph, A, Rezapour, T, Tavakoli, H, Zare-Bidoky, M, Zilverstand, A, Steele, D, Moeller, SJ, Paulus, MP, Baldacchino, A & Ekhtiari, H 2019, 'A Roadmap for Integrating Neuroscience into Addiction Treatment: A Consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine', Frontiers in Psychiatry, vol. 10, 877, pp. 1-23. https://doi.org/10.3389/fpsyt.2019.00877

A Roadmap for Integrating Neuroscience into Addiction Treatment : A Consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine. / Verdejo-Garcia, Antonio (Lead / Corresponding author); Lorenzetti, Valentina; Manning, Victoria; Piercy, Hugh; Bruno, Raimondo; Hester, Rob; Pennington, David; Tolomeo, Serenella; Arunogiri, Shalini; Bates, Marsha E.; Bowden-Jones, Henrietta; Campanella, Salvatore; Daughters, Stacey ; Kouimtsidis, Christos; Lubman, Dan I.; Meyerhoff, Dieter J.; Ralph, Annaketurah; Rezapour, Tara; Tavakoli, Hosna; Zare-Bidoky, Mehran; Zilverstand, Anna; Steele, Douglas; Moeller, Scott J.; Paulus, Martin P. ; Baldacchino, Alex; Ekhtiari, Hamed.

In: Frontiers in Psychiatry, Vol. 10, 877, 23.12.2019, p. 1-23.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Roadmap for Integrating Neuroscience into Addiction Treatment

T2 - A Consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine

AU - Verdejo-Garcia, Antonio

AU - Lorenzetti, Valentina

AU - Manning, Victoria

AU - Piercy, Hugh

AU - Bruno, Raimondo

AU - Hester, Rob

AU - Pennington, David

AU - Tolomeo, Serenella

AU - Arunogiri, Shalini

AU - Bates, Marsha E.

AU - Bowden-Jones, Henrietta

AU - Campanella, Salvatore

AU - Daughters, Stacey

AU - Kouimtsidis, Christos

AU - Lubman, Dan I.

AU - Meyerhoff, Dieter J.

AU - Ralph, Annaketurah

AU - Rezapour, Tara

AU - Tavakoli, Hosna

AU - Zare-Bidoky, Mehran

AU - Zilverstand, Anna

AU - Steele, Douglas

AU - Moeller, Scott J.

AU - Paulus, Martin P.

AU - Baldacchino, Alex

AU - Ekhtiari, Hamed

N1 - AV-G is supported by Australian Medical Research Future Fund Fellowship (MRF1141214). DM is supported by NIH R01DA039903. MB receives support from NIH R01AA023667. DLP is supported by the Office of Research and Development, Clinical Science Research and Development (CSR&D), Department of Veterans Affairs, Career Development Award—2 (1IK2CX001510-01). SJM was supported by NIH K01DA037452.

PY - 2019/12/23

Y1 - 2019/12/23

N2 - Although there is general consensus that altered brain structure and function underpins addictive disorders, clinicians working in addiction treatment rarely incorporate neuroscience-informed approaches into their practice. We recently launched the Neuroscience Interest Group within the International Society of Addiction Medicine (ISAMNIG) to promote initiatives to bridge this gap. This article summarises the ISAM-NIG key priorities and strategies to achieve implementation of addiction neuroscience knowledge and tools forthe assessment and treatment of substance use disorders. We cover two assessment areas: cognitive assessment and neuroimaging, and two interventional areas: cognitive training/remediation and neuromodulation, where we identify key challenges and proposed solutions. We reason that incorporating cognitive assessment into clinical settings requires the identification of constructs that predict meaningful clinical outcomes. Other requirements are the development of measures that are easily-administered, reliable and ecologically-valid. Translation of neuroimaging techniques requires the development of diagnostic and prognostic biomarkers and testing the cost-effectiveness of these biomarkers in individualised prediction algorithms for relapse prevention and treatment selection. Integration of cognitive assessments with neuroimaging can provide multilevel targets including neural, cognitive, and behavioural outcomes for neuroscience-informed interventions. Application of neuroscience-informed interventions including cognitive training/remediation and neuromodulation requires clear pathways to design interventions based on multilevel targets, additional evidence from randomised trials and subsequent clinical implementation, including evaluation of cost-effectiveness. We propose to address these challenges by promoting international collaboration between researchers and clinicians, developing harmonised protocols and data management systems, and prioritising multi-site research that focuses on improving clinical outcomes.

AB - Although there is general consensus that altered brain structure and function underpins addictive disorders, clinicians working in addiction treatment rarely incorporate neuroscience-informed approaches into their practice. We recently launched the Neuroscience Interest Group within the International Society of Addiction Medicine (ISAMNIG) to promote initiatives to bridge this gap. This article summarises the ISAM-NIG key priorities and strategies to achieve implementation of addiction neuroscience knowledge and tools forthe assessment and treatment of substance use disorders. We cover two assessment areas: cognitive assessment and neuroimaging, and two interventional areas: cognitive training/remediation and neuromodulation, where we identify key challenges and proposed solutions. We reason that incorporating cognitive assessment into clinical settings requires the identification of constructs that predict meaningful clinical outcomes. Other requirements are the development of measures that are easily-administered, reliable and ecologically-valid. Translation of neuroimaging techniques requires the development of diagnostic and prognostic biomarkers and testing the cost-effectiveness of these biomarkers in individualised prediction algorithms for relapse prevention and treatment selection. Integration of cognitive assessments with neuroimaging can provide multilevel targets including neural, cognitive, and behavioural outcomes for neuroscience-informed interventions. Application of neuroscience-informed interventions including cognitive training/remediation and neuromodulation requires clear pathways to design interventions based on multilevel targets, additional evidence from randomised trials and subsequent clinical implementation, including evaluation of cost-effectiveness. We propose to address these challenges by promoting international collaboration between researchers and clinicians, developing harmonised protocols and data management systems, and prioritising multi-site research that focuses on improving clinical outcomes.

KW - Neuroscience

KW - Addiction Medicine

KW - Treatment

KW - Substance Use Disorder

KW - fMRI

KW - Neuromodulation

KW - Cognition

KW - Neuropsychological Assessment

KW - Cognitive Remediation

KW - Cognitive Training

U2 - 10.3389/fpsyt.2019.00877

DO - 10.3389/fpsyt.2019.00877

M3 - Article

C2 - 31920740

VL - 10

SP - 1

EP - 23

JO - Frontiers in Psychiatry

JF - Frontiers in Psychiatry

SN - 1664-0640

M1 - 877

ER -